Publications
Publications published since 2000 from OUS - Department of Gynaecological Oncology
503 publications found
Publications 2022
-
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
Cytopathology, 33 (4), 479-492
DOI 10.1111/cyt.13126, PubMed 35398934 -
Nonepithelial ovarian cancer - the current clinical practice in the Nordic countries. Survey from the surgical subcommittee of the Nordic society of gynecological oncology (NSGO)
Acta Oncol, 1-7 (in press)
DOI 10.1080/0284186X.2022.2088249, PubMed 35762031 -
Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
Virchows Arch, 480 (5), 1031-1039
DOI 10.1007/s00428-022-03291-x, PubMed 35124717 -
Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?
Int J Gynecol Cancer (in press)
DOI 10.1136/ijgc-2022-003361, PubMed 35680138 -
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
Cancer (in press)
DOI 10.1002/cncr.34350, PubMed 35714310 -
miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
Mol Oncol, 16 (6), 1402-1419
DOI 10.1002/1878-0261.13184, PubMed 35064630 -
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Gynecol Oncol, 166 (1), 36-43
DOI 10.1016/j.ygyno.2022.04.012, PubMed 35550709 -
Early referral to a palliative team improves end-of-life care among gynecological cancer patients: a retrospective, population-based study
Int J Gynecol Cancer, 32 (2), 181-188
DOI 10.1136/ijgc-2021-002898, PubMed 34987096 -
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Gynecol Oncol, 164 (3), 498-504
DOI 10.1016/j.ygyno.2021.12.025, PubMed 35063276 -
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification
Gynecol Oncol, 165 (2), 230-238
DOI 10.1016/j.ygyno.2022.02.024, PubMed 35277281
Publications 2021
-
Self-reported cognitive impairment in cervical cancer survivors: A cross-sectional study
Psychooncology, 31 (2), 298-305
DOI 10.1002/pon.5818, PubMed 34516040 -
International Gynaecological Cancer Society (IGCS) 2020 Annual Global Meeting: Twitter activity analysis
Int J Gynecol Cancer, 31 (11), 1453-1458
DOI 10.1136/ijgc-2021-002781, PubMed 34489352 -
Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis
Virchows Arch, 479 (2), 419-424
DOI 10.1007/s00428-021-03057-x, PubMed 33595736 -
Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
J Clin Med, 10 (14)
DOI 10.3390/jcm10143094, PubMed 34300260 -
Advances in management of nonendometrioid endometrial carcinoma, with an emphasis on the sentinel lymph node technique
Curr Opin Oncol, 33 (5), 457-463
DOI 10.1097/CCO.0000000000000777, PubMed 34264897 -
Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer
Sci Rep, 11 (1), 23463
DOI 10.1038/s41598-021-02820-z, PubMed 34873230 -
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
N Engl J Med, 385 (23), 2123-2131
DOI 10.1056/NEJMoa2103294, PubMed 34874631 -
Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer
Biomarkers, 26 (4), 302-308
DOI 10.1080/1354750X.2021.1891291, PubMed 33645339 -
The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness
Acta Oncol, 60 (4), 434-443
DOI 10.1080/0284186X.2021.1891281, PubMed 33651647 -
Association of patient-reported outcomes and ovarian cancer recurrence
Int J Gynecol Cancer, 31 (9), 1248-1259
DOI 10.1136/ijgc-2021-002550, PubMed 34489355 -
Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification
Cancers (Basel), 13 (22)
DOI 10.3390/cancers13225848, PubMed 34831000 -
Association of Circulating miRNA Expression with Preeclampsia, Its Onset, and Severity
Diagnostics (Basel), 11 (3)
DOI 10.3390/diagnostics11030476, PubMed 33800458 -
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 31 1, 20 -
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 31 2, 18 -
Salvage Radiation for Pelvic Relapse after Surgically Treated Endometrial Cancer
Cancers (Basel), 13 (6)
DOI 10.3390/cancers13061367, PubMed 33803531 -
Distress, problems and unmet rehabilitation needs after treatment for gynecological cancer
Acta Obstet Gynecol Scand, 101 (3), 313-322
DOI 10.1111/aogs.14310, PubMed 34964982 -
Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report
Eur J Cancer, 148, 124-133
DOI 10.1016/j.ejca.2021.02.022, PubMed 33743481 -
Long-term oncological outcomes and recurrence patterns in early-stage cervical cancer treated with minimally invasive versus abdominal radical hysterectomy: The Norwegian Radium Hospital experience
Gynecol Oncol, 162 (2), 284-291
DOI 10.1016/j.ygyno.2021.05.028, PubMed 34083029 -
Self-management and adherence to recommended follow-up after gynaecological cancer: results from the international InCHARGE study
Int J Gynecol Cancer, 31 (8), 1106-1115
DOI 10.1136/ijgc-2020-002377, PubMed 33858949 -
Age-related differences in self-report and objective measures of cognitive function in older patients prior to chemotherapy
Nurs Open, 9 (2), 1040-1051
DOI 10.1002/nop2.1141, PubMed 34878233 -
Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer
Am J Obstet Gynecol, 225 (4), 407.e1-407.e16
DOI 10.1016/j.ajog.2021.05.007, PubMed 34019887 -
Lifestyle and Empowerment Techniques in Survivorship of Gynaecologic Oncology (LETSGO study): a study protocol for a multicentre longitudinal interventional study using mobile health technology and biobanking
BMJ Open, 11 (7), e050930
DOI 10.1136/bmjopen-2021-050930, PubMed 34253678
Publications 2020
-
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
EBioMedicine, 57, 102841
DOI 10.1016/j.ebiom.2020.102841, PubMed 32580139 -
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Int J Gynecol Cancer, 30 (12), 1997-2001
DOI 10.1136/ijgc-2020-001572, PubMed 32606097 -
MRI Distinguishes Tumor Hypoxia Levels of Different Prognostic and Biological Significance in Cervical Cancer
Cancer Res, 80 (18), 3993-4003
DOI 10.1158/0008-5472.CAN-20-0950, PubMed 32606004 -
Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study
Int J Mol Sci, 21 (19)
DOI 10.3390/ijms21197288, PubMed 33023154 -
Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol
Int J Gynecol Cancer, 30 (9), 1444-1449
DOI 10.1136/ijgc-2020-001528, PubMed 32586892 -
Prognostic Value of the Diversity of Nuclear Chromatin Compartments in Gynaecological Carcinomas
Cancers (Basel), 12 (12)
DOI 10.3390/cancers12123838, PubMed 33352679 -
Genoprotective activities of plant natural substances in cancer and chemopreventive strategies in the context of 3P medicine
EPMA J, 11 (2), 261-287
DOI 10.1007/s13167-020-00210-5, PubMed 32547652 -
Assessment of palliative care training in gynaecological oncology: a survey among European Network of Young Gynae-Oncologists (ENYGO) members
BMJ Support Palliat Care (in press)
DOI 10.1136/bmjspcare-2020-002233, PubMed 32958506 -
Subspecialty training in Europe: a report by the European Network of Young Gynaecological Oncologists
Int J Gynecol Cancer, 31 (4), 575-584
DOI 10.1136/ijgc-2020-002176, PubMed 33361458 -
Systematic treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 30 1, 15 -
Elderly gynaecological cancer patients at risk for poor end of life care: a population-based study from the Swedish Register of Palliative Care
Acta Oncol, 59 (6), 636-643
DOI 10.1080/0284186X.2020.1744717, PubMed 32238040 -
DCE-MRI of locally-advanced carcinoma of the uterine cervix: Tofts analysis versus non-model-based analyses
Radiat Oncol, 15 (1), 79
DOI 10.1186/s13014-020-01526-2, PubMed 32293487 -
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
Gynecol Oncol, 159 (2), 442-448
DOI 10.1016/j.ygyno.2020.09.006, PubMed 32981695 -
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum
J Clin Oncol, 38 (32), 3753-3762
DOI 10.1200/JCO.20.01164, PubMed 32822286 -
Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care
Int J Gynecol Cancer, 30 (11), 1748-1756
DOI 10.1136/ijgc-2020-001403, PubMed 32784203 -
Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
JAMA Netw Open, 3 (1), e1918939
DOI 10.1001/jamanetworkopen.2019.18939, PubMed 31922558 -
COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers
Int J Gynecol Cancer, 30 (5), 561-563
DOI 10.1136/ijgc-2020-001419, PubMed 32221023 -
International Gynecologic Cancer Society 2019 meeting summary
Int J Gynecol Cancer, 30 (2), 167-173
DOI 10.1136/ijgc-2019-001146, PubMed 32029483 -
Base rate of ovarian cancer on algorithms in patients with a pelvic mass
Int J Gynecol Cancer, 30 (11), 1775-1779
DOI 10.1136/ijgc-2020-001416, PubMed 32699016 -
Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses
J Appl Lab Med, 5 (2), 263-272
DOI 10.1093/jalm/jfz012, PubMed 32445385 -
The role of plant-derived natural substances as immunomodulatory agents in carcinogenesis
J Cancer Res Clin Oncol, 146 (12), 3137-3154
DOI 10.1007/s00432-020-03424-2, PubMed 33063131 -
Flavonoids against the Warburg phenotype-concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism
EPMA J, 11 (3), 377-398
DOI 10.1007/s13167-020-00217-y, PubMed 32843908 -
Aberrantly Methylated cfDNA in Body Fluids as a Promising Diagnostic Tool for Early Detection of Breast Cancer
Clin Breast Cancer, 20 (6), e711-e722
DOI 10.1016/j.clbc.2020.05.009, PubMed 32792225 -
Preferences for follow up in long-term survivors after cervical cancer
Acta Obstet Gynecol Scand, 99 (9), 1253-1259
DOI 10.1111/aogs.13855, PubMed 32232835 -
Rho GTPases in Gynecologic Cancers: In-Depth Analysis toward the Paradigm Change from Reactive to Predictive, Preventive, and Personalized Medical Approach Benefiting the Patient and Healthcare
Cancers (Basel), 12 (5)
DOI 10.3390/cancers12051292, PubMed 32443784 -
Cold Atmospheric Pressure Plasma (CAP) as a New Tool for the Management of Vulva Cancer and Vulvar Premalignant Lesions in Gynaecological Oncology
Int J Mol Sci, 21 (21)
DOI 10.3390/ijms21217988, PubMed 33121141
Publications 2019
-
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
Clin Cancer Res, 25 (7), 2155-2165
DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134 -
Endometrial cancer during pregnancy: management strategies
Int J Gynecol Cancer, 29 (7), 1221-1224
DOI 10.1136/ijgc-2019-000756, PubMed 31434687 -
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Gynecol Oncol, 152 (3), 560-567
DOI 10.1016/j.ygyno.2018.12.009, PubMed 30638768 -
Mitochondrial Function of CKS2 Oncoprotein Links Oxidative Phosphorylation with Cell Division in Chemoradioresistant Cervical Cancer
Neoplasia, 21 (4), 353-362
DOI 10.1016/j.neo.2019.01.002, PubMed 30856376 -
Summary of landmark papers published between August 2018 and May 2019
Int. J. Gynecol. Cancer, 29 1, 1-5
DOI 10.1136/ijgc-2019-000738 -
Pharmacokinetic analysis of DCE-MRI data of locally advanced cervical carcinoma with the Brix model
Acta Oncol, 58 (6), 828-837
DOI 10.1080/0284186X.2019.1580386, PubMed 30810443 -
Reference MicroRNAs for RT-qPCR Assays in Cervical Cancer Patients and Their Application to Studies of HPV16 and Hypoxia Biomarkers
Transl Oncol, 12 (3), 576-584
DOI 10.1016/j.tranon.2018.12.010, PubMed 30660934 -
Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects
Int J Gynecol Cancer, 29 (1), 181-187
DOI 10.1136/ijgc-2018-000021, PubMed 30640702 -
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer
Cochrane Database Syst Rev (10), CD012160
DOI 10.1002/14651858.CD012160.pub2, PubMed 31588998 -
Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials
Obstet. Gynecol. Surv., 74 (3), 156-158
DOI 10.1097/01.ogx.0000554460.78765.59
Publications 2018
-
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
Gynecol Oncol, 152 (1), 53-60
DOI 10.1016/j.ygyno.2018.08.036, PubMed 30449719 -
Chromatin organisation and cancer prognosis: a pan-cancer study
Lancet Oncol, 19 (3), 356-369
DOI 10.1016/S1470-2045(17)30899-9, PubMed 29402700 -
Medical treatment of primary and recurrent cervical cancer
Int. J. Gynecol. Cancer, 28 4, 29 -
Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)
Cancer Chemother Pharmacol, 83 (1), 97-105
DOI 10.1007/s00280-018-3706-5, PubMed 30368585 -
Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance
Gynecol Oncol, 150 (2), 239-246
DOI 10.1016/j.ygyno.2018.05.020, PubMed 29807697 -
PREFACE
Int. J. Gynecol. Cancer, 28 4, 2 -
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
Ann Intern Med, 168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712 -
Association Between Proportion of Nuclei With High Chromatin Entropy and Prognosis in Gynecological Cancers
J Natl Cancer Inst, 110 (12), 1400-1408
DOI 10.1093/jnci/djy063, PubMed 29684152 -
Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients - a comparative cohort study
Acta Oncol, 57 (8), 1100-1108
DOI 10.1080/0284186X.2018.1440085, PubMed 29451070 -
DCE-MRI-Derived Measures of Tumor Hypoxia and Interstitial Fluid Pressure Predict Outcomes in Cervical Carcinoma
Int J Radiat Oncol Biol Phys, 102 (4), 1193-1201
DOI 10.1016/j.ijrobp.2018.04.035, PubMed 29859790 -
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455 -
Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor
Acta Obstet Gynecol Scand, 98 (2), 240-249
DOI 10.1111/aogs.13477, PubMed 30289161 -
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
Acta Obstet Gynecol Scand, 97 (8), 956-965
DOI 10.1111/aogs.13361, PubMed 29790149
Publications 2017
-
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905 -
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Virchows Arch, 471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014 -
A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer
Int J Gynecol Cancer, 27 (4), 743-747
DOI 10.1097/IGC.0000000000000959, PubMed 28375931 -
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999 -
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432 -
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
Am J Surg Pathol, 41 (9), 1231-1237
DOI 10.1097/PAS.0000000000000894, PubMed 28622181 -
Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
Acta Obstet Gynecol Scand, 96 (5), 547-555
DOI 10.1111/aogs.13120, PubMed 28236297 -
[Properties of cancer cell DNA affects the prognosis]
Tidsskr Nor Laegeforen, 137 (19)
DOI 10.4045/tidsskr.16.0966, PubMed 29043733 -
Characteristics of tumor cell DNA affect prognosis
Tidsskr. Nor. Laegeforen., 137 (19), 1519-1523 -
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630 -
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
DOI 10.1038/bjc.2016.435, PubMed 28118323 -
Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
Int J Gynecol Cancer, 27 (6), 1274-1282
DOI 10.1097/IGC.0000000000000981, PubMed 28498237 -
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
Int J Gynecol Cancer, 27 (5), 1046-1050
DOI 10.1097/IGC.0000000000000982, PubMed 28525497 -
Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
Acta Oncol, 56 (5), 675-681
DOI 10.1080/0284186X.2017.1294762, PubMed 28447564 -
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
Gynecol Oncol, 145 (3), 543-548
DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187 -
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
Ann Surg Oncol, 24 (9), 2720-2726
DOI 10.1245/s10434-017-5919-y, PubMed 28608122 -
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
Eur J Surg Oncol, 45 (1), 67-74
DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961 -
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
Gynecol Oncol, 145 (1), 148-153
DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195 -
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395 -
A study of chronic fatigue in Norwegian cervical cancer survivors
Gynecol Oncol, 146 (3), 630-635
DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254 -
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
Acta Obstet Gynecol Scand, 96 (10), 1162-1169
DOI 10.1111/aogs.13199, PubMed 28795770 -
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro Oncol, 19 (7), 976-985
DOI 10.1093/neuonc/now272, PubMed 28040713 -
Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
Acta Oncol, 56 (10), 1302-1309
DOI 10.1080/0284186X.2017.1330554, PubMed 28548875 -
A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
Int J Gynecol Cancer, 27 (3), 620-626
DOI 10.1097/IGC.0000000000000917, PubMed 28187096
Publications 2016
-
Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
Obstet Gynecol, 128 (6), 1265-1273
DOI 10.1097/AOG.0000000000001777, PubMed 27824756 -
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
Am J Clin Pathol, 145 (4), 449-58
DOI 10.1093/ajcp/aqw030, PubMed 27149024 -
Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Clin Cancer Res, 22 (16), 4067-76
DOI 10.1158/1078-0432.CCR-15-2322, PubMed 27012812 -
Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
PLoS One, 11 (5), e0156259
DOI 10.1371/journal.pone.0156259, PubMed 27244197 -
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
DOI 10.1007/s13277-016-4940-2, PubMed 26867771 -
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
Gynecol Oncol, 142 (3), 458-64
DOI 10.1016/j.ygyno.2016.06.023, PubMed 27444035 -
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Gynecol Oncol, 140 (3), 457-62
DOI 10.1016/j.ygyno.2016.01.022, PubMed 26807488 -
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
PLoS One, 11 (9), e0162502
DOI 10.1371/journal.pone.0162502, PubMed 27622508 -
Medical treatment of primary or recurrent cervical cancer
Int. J. Gynecol. Cancer, 26 1, 42-43 -
Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
Int. J. Gynecol. Cancer, 26 1, 5-8 -
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Ann Oncol, 27 (8), 1505-10
DOI 10.1093/annonc/mdw238, PubMed 27407100 -
Preface
Int. J. Gynecol. Cancer, 26 1, 2 -
Life - Literature for ENYGO
Int. J. Gynecol. Cancer, 26 4, 2-73 -
Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
BMJ Open, 6 (11), e013728
DOI 10.1136/bmjopen-2016-013728, PubMed 28186949 -
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
Oncologist, 21 (6), 745-54
DOI 10.1634/theoncologist.2015-0239, PubMed 27009938 -
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
N Engl J Med, 375 (22), 2154-2164
DOI 10.1056/NEJMoa1611310, PubMed 27717299 -
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471 -
Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
Eur J Surg Oncol, 42 (4), 513-22
DOI 10.1016/j.ejso.2015.12.014, PubMed 26843445 -
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577 -
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecol Oncol, 144 (1), 65-71
DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723 -
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
DOI 10.12892/ejgo3007.2016, PubMed 27352555 -
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
Oncotarget, 7 (11), 12267-85
DOI 10.18632/oncotarget.7860, PubMed 26943585 -
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
Ann Oncol, 27 (9), 1733-9
DOI 10.1093/annonc/mdw236, PubMed 27287207 -
Medical treatment of primary ovarian cancer
Int. J. Gynecol. Cancer, 26 1, 9-11 -
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
Br J Cancer, 115 (2), 228-35
DOI 10.1038/bjc.2016.194, PubMed 27351218
Publications 2015
-
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
PLoS One, 10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914 -
Psychological distress related to BRCA testing in ovarian cancer patients
Fam Cancer, 14 (4), 495-504
DOI 10.1007/s10689-015-9811-2, PubMed 25980896 -
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Hum Pathol, 48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230 -
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet Oncol, 17 (1), 78-89
DOI 10.1016/S1470-2045(15)00366-6, PubMed 26590673 -
MicroRNAs in Ovarian Cancer
Hum Pathol, 46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350 -
Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer
Epigenetics, 10 (10), 970-80
DOI 10.1080/15592294.2015.1085140, PubMed 26291246 -
Body mass index, diabetes and survival after diagnosis of endometrial cancer: A report from the HUNT-Survey
Gynecol Oncol, 139 (3), 476-80
DOI 10.1016/j.ygyno.2015.09.088, PubMed 26434365 -
The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer
ESC Heart Fail, 2 (3), 142-149
DOI 10.1002/ehf2.12048, PubMed 28834675 -
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Gynecol Oncol, 139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338 -
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Mol Cancer, 14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687 -
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Lancet Oncol, 16 (8), 928-36
DOI 10.1016/S1470-2045(15)00086-8, PubMed 26115797 -
Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy
Radiother Oncol, 117 (2), 333-7
DOI 10.1016/j.radonc.2015.09.014, PubMed 26372344 -
Alopecia as surrogate marker for chemotherapy response in patients with primary epithelial ovarian cancer: a metaanalysis of four prospective randomised phase III trials with 5114 patients
Eur J Cancer, 51 (7), 825-32
DOI 10.1016/j.ejca.2015.01.008, PubMed 25771433 -
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Genome Med, 7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652 -
Smoking, obesity and the risk of pituitary adenoma: a large prospective cohort study (The HUNT Study)
Eur J Epidemiol, 31 (1), 95-8
DOI 10.1007/s10654-015-0033-6, PubMed 25903163
Publications 2014
-
Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma
Int J Gynecol Cancer, 24 (9 Suppl 3), S67-72
DOI 10.1097/IGC.0000000000000205, PubMed 25033257 -
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994 -
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216 -
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
Hum Pathol, 45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803 -
Ovarian cancer: diagnostic, biological and prognostic aspects
Womens Health (Lond), 10 (5), 519-33
DOI 10.2217/whe.14.37, PubMed 25335543 -
The clinical and diagnostic role of microRNAs in ovarian carcinoma
Gynecol Oncol, 133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546 -
The role of the tumor stroma in ovarian cancer
Front Oncol, 4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785 -
Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract
Int J Gynecol Cancer, 24 (9 Suppl 3), S78-82
DOI 10.1097/IGC.0000000000000239, PubMed 25341585 -
Peritumoral interstitial fluid flow velocity predicts survival in cervical carcinoma
Radiother Oncol, 113 (1), 132-8
DOI 10.1016/j.radonc.2014.09.011, PubMed 25443501 -
CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients
PLoS One, 9 (11), e112209
DOI 10.1371/journal.pone.0112209, PubMed 25380303 -
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
BMC Cancer, 14, 68
DOI 10.1186/1471-2407-14-68, PubMed 24498853 -
Genomic profile of ovarian carcinomas
BMC Cancer, 14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194 -
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
PLoS Biol, 12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521 -
Entropy-based adaptive nuclear texture features are independent prognostic markers in a total population of uterine sarcomas
Cytometry A, 87 (4), 315-25
DOI 10.1002/cyto.a.22601, PubMed 25483227 -
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial
J Clin Oncol, 32 (13), 1302-8
DOI 10.1200/JCO.2013.51.4489, PubMed 24637997 -
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma
Int J Gynecol Cancer, 24 (9 Suppl 3), S83-9
DOI 10.1097/IGC.0000000000000264, PubMed 25341586 -
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290 -
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323 -
Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010)
Eur J Cancer, 50 (11), 1942-50
DOI 10.1016/j.ejca.2014.03.288, PubMed 24857045 -
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159 -
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085 -
Exosome-derived miRNAs and ovarian carcinoma progression
Carcinogenesis, 35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027 -
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
BMC Cancer, 14, 80
DOI 10.1186/1471-2407-14-80, PubMed 24512620 -
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
BMC Cancer, 14, 937
DOI 10.1186/1471-2407-14-937, PubMed 25494701
Publications 2013
-
Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome
Radiother Oncol, 107 (1), 117-22
DOI 10.1016/j.radonc.2012.11.007, PubMed 23333024 -
High levels of genomic aberrations in serous ovarian cancers are associated with better survival
PLoS One, 8 (1), e54356
DOI 10.1371/journal.pone.0054356, PubMed 23372714 -
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
Hum Pathol, 45 (4), 691-700
DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798 -
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953 -
Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy
Gynecol Oncol, 131 (2), 437-44
DOI 10.1016/j.ygyno.2013.08.014, PubMed 23994107 -
Identification of eight candidate target genes of the recurrent 3p12-p14 loss in cervical cancer by integrative genomic profiling
J Pathol, 230 (1), 59-69
DOI 10.1002/path.4168, PubMed 23335387 -
Long-term outcomes after pelvic radiation for early-stage endometrial cancer
J Clin Oncol, 31 (31), 3951-6
DOI 10.1200/JCO.2013.48.8023, PubMed 24019546 -
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
Gynecol Oncol, 131 (2), 330-5
DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518 -
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
Lancet Oncol, 14 (3), 236-43
DOI 10.1016/S1470-2045(12)70567-3, PubMed 23333117 -
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671 -
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Hum Pathol, 44 (12), 2677-83
DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004 -
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974
Publications 2012
-
Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
BMC Cancer, 12, 454
DOI 10.1186/1471-2407-12-454, PubMed 23039163 -
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560 -
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
Gynecol Oncol, 128 (2), 349-55
DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314 -
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
Gynecol Oncol, 128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104 -
ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival
PLoS One, 7 (9), e46317
DOI 10.1371/journal.pone.0046317, PubMed 23029477 -
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
Acta Obstet Gynecol Scand, 91 (3), 308-17
DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605 -
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation
Ann Surg Oncol, 20 (4), 1348-54
DOI 10.1245/s10434-012-2673-z, PubMed 23054114 -
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Clin Cancer Res, 18 (11), 3197-206
DOI 10.1158/1078-0432.CCR-12-0056, PubMed 22492981 -
Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI
Cancer Res, 72 (20), 5285-95
DOI 10.1158/0008-5472.CAN-12-1085, PubMed 22890239 -
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403 -
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409 -
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154 -
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921 -
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637 -
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk
PLoS One, 7 (4), e36263
DOI 10.1371/journal.pone.0036263, PubMed 22558411 -
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
Ann Oncol, 24 (4), 937-43
DOI 10.1093/annonc/mds538, PubMed 23104722 -
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells
BMC Cancer, 12, 201
DOI 10.1186/1471-2407-12-201, PubMed 22642602 -
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-2619
DOI 10.1093/annonc/mds060, PubMed 22539562 -
Association between hysterectomy with ovarian preservation and cardiovascular disease in a Norwegian population-based sample
Gynecol Obstet Invest, 75 (1), 61-7
DOI 10.1159/000345072, PubMed 23220872 -
The prognostic value of adaptive nuclear texture features from patient gray level entropy matrices in early stage ovarian cancer
Anal Cell Pathol (Amst), 35 (4), 305-14
DOI 10.3233/ACP-2012-0065, PubMed 22596183 -
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
Virchows Arch, 461 (3), 291-8
DOI 10.1007/s00428-012-1275-2, PubMed 22824999 -
Diagnosis and treatment of sarcoma of the uterus. A review
Acta Oncol, 51 (6), 694-705
DOI 10.3109/0284186X.2012.689111, PubMed 22793037 -
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Eur J Cancer, 48 (14), 2146-54
DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201 -
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906 -
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum Pathol, 43 (11), 2062-9
DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351 -
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
Br J Cancer, 107 (4), 588-91
DOI 10.1038/bjc.2012.307, PubMed 22836511 -
Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
Int J Mol Sci, 13 (10), 12925-38
DOI 10.3390/ijms131012925, PubMed 23202930
Publications 2011
-
Dynamic contrast-enhanced MRI of cervical cancers: temporal percentile screening of contrast enhancement identifies parameters for prediction of chemoradioresistance
Int J Radiat Oncol Biol Phys, 82 (3), e485-92
DOI 10.1016/j.ijrobp.2011.05.050, PubMed 22014954 -
Pharmacokinetic analysis and k-means clustering of DCEMR images for radiotherapy outcome prediction of advanced cervical cancers
Acta Oncol, 50 (6), 859-65
DOI 10.3109/0284186X.2011.578586, PubMed 21767185 -
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
Cancer Chemother Pharmacol, 69 (2), 467-75
DOI 10.1007/s00280-011-1716-7, PubMed 21822668 -
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
Hum Pathol, 43 (5), 669-74
DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113 -
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
Tumour Biol, 32 (3), 589-96
DOI 10.1007/s13277-011-0157-6, PubMed 21350924 -
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Hum Pathol, 43 (4), 496-505
DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111 -
"The impact of cancer scale" version 1: psychometric testing of the Norwegian translation in a heterogeneous sample of cancer survivors
Qual Life Res, 21 (8), 1459-70
DOI 10.1007/s11136-011-0053-y, PubMed 22045155 -
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
Hum Pathol, 42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424 -
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
Cytopathology, 22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542 -
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
Hum Pathol, 43 (4), 529-35
DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883 -
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
Mol Pharm, 8 (6), 2080-8
DOI 10.1021/mp200240a, PubMed 21761824 -
Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists
Int J Gynecol Cancer, 21 (8), 1500-6
DOI 10.1097/IGC.0b013e3182202d17, PubMed 21720256 -
Phosphorylation of EGFR measured with in situ proximity ligation assay: relationship to EGFR protein level and gene dosage in cervical cancer
Radiother Oncol, 101 (1), 152-7
DOI 10.1016/j.radonc.2011.05.052, PubMed 21680035 -
Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer
Clin Cancer Res, 17 (16), 5501-12
DOI 10.1158/1078-0432.CCR-11-0297, PubMed 21737508 -
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408 -
Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization
Mol Oncol, 6 (1), 98-107
DOI 10.1016/j.molonc.2011.10.002, PubMed 22062770 -
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-53
DOI 10.1002/cncr.26449, PubMed 22009736 -
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians
Cancer Cell, 19 (2), 273-82
DOI 10.1016/j.ccr.2010.12.019, PubMed 21316605 -
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
Ann Oncol, 22 (11), 2417-2423
DOI 10.1093/annonc/mdr001, PubMed 21402619 -
The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome
Eur J Gynaecol Oncol, 32 (4), 369-76
PubMed 21941955 -
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701 -
A phase 3 trial of bevacizumab in ovarian cancer
N Engl J Med, 365 (26), 2484-96
DOI 10.1056/NEJMoa1103799, PubMed 22204725 -
Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium
Ann Oncol, 23 (5), 1178-1184
DOI 10.1093/annonc/mdr368, PubMed 21965471 -
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
Int J Gynecol Cancer, 21 (2), 419-23
DOI 10.1097/IGC.0b013e3182070f17, PubMed 21270624 -
Robot-assisted laparoscopic radical hysterectomy: comparison with total laparoscopic hysterectomy and abdominal radical hysterectomy; one surgeon's experience at the Norwegian Radium Hospital
Gynecol Oncol, 121 (3), 600-4
DOI 10.1016/j.ygyno.2011.02.002, PubMed 21353294 -
First-line therapy in ovarian cancer trials
Int J Gynecol Cancer, 21 (4), 756-62
DOI 10.1097/IGC.0b013e31821ce75d, PubMed 21543937 -
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
Ann Surg Oncol, 19 (2), 597-604
DOI 10.1245/s10434-011-1873-2, PubMed 21732142 -
miRNA profiling along tumour progression in ovarian carcinoma
J Cell Mol Med, 15 (7), 1593-602
DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115 -
Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
Eur J Cancer, 47 Suppl 3, S88-92
DOI 10.1016/S0959-8049(11)70152-6, PubMed 21944035 -
Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer
J Clin Oncol, 29 (31), 4076-8
DOI 10.1200/JCO.2011.36.9785, PubMed 21931032 -
A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer
J Cancer Surviv, 5 (2), 208-16
DOI 10.1007/s11764-011-0172-z, PubMed 21259075 -
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort
Br J Cancer, 105 (7), 890-6
DOI 10.1038/bjc.2011.328, PubMed 21878937
Publications 2010
-
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
Int J Gynecol Cancer, 20 (9), 1448-55
DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029 -
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
Hum Pathol, 41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512 -
New determinates of disease progression and outcome in metastatic ovarian carcinoma
Histol Histopathol, 25 (12), 1591-609
DOI 10.14670/HH-25.1591, PubMed 20886439 -
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer
J Clin Oncol, 28 (27), 4162-9
DOI 10.1200/JCO.2009.27.4696, PubMed 20733132 -
POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas
PLoS One, 5 (11), e13837
DOI 10.1371/journal.pone.0013837, PubMed 21079801 -
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
Clin Exp Metastasis, 27 (3), 161-72
DOI 10.1007/s10585-010-9315-2, PubMed 20213325 -
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies
Eur J Cancer, 46 (13), 2422-31
DOI 10.1016/j.ejca.2010.06.002, PubMed 20619634 -
A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
Br J Cancer, 102 (6), 957-65
DOI 10.1038/sj.bjc.6605594, PubMed 20197765 -
Genomic aberrations in borderline ovarian tumors
J Transl Med, 8, 21
DOI 10.1186/1479-5876-8-21, PubMed 20184781 -
Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes
Genes Chromosomes Cancer, 49 (11), 1046-53
DOI 10.1002/gcc.20813, PubMed 20725991 -
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer
Int J Gynecol Cancer, 20 (2), 233-9
DOI 10.1111/igc.0b013e3181ca5ff4, PubMed 20169665 -
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
Am J Pathol, 177 (3), 1087-94
DOI 10.2353/ajpath.2010.100316, PubMed 20671266 -
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
Int J Gynecol Pathol, 29 (6), 572-8
DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853 -
Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation
BMC Cancer, 10, 493
DOI 10.1186/1471-2407-10-493, PubMed 20843305 -
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
J Clin Oncol, 28 (20), 3323-9
DOI 10.1200/JCO.2009.25.7519, PubMed 20498395 -
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Lancet, 376 (9747), 1155-63
DOI 10.1016/S0140-6736(10)61268-8, PubMed 20888993 -
Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes
Int J Med Robot, 6 (2), 132-5
DOI 10.1002/rcs.295, PubMed 20049750 -
Comparison between robot-assisted laparoscopic radical hysterectomy (RRH) and abdominal radical hysterectomy (ARH): a case control study from EIO/Milan
Gynecol Oncol, 117 (2), 389; author reply 389-90
DOI 10.1016/j.ygyno.2010.01.032, PubMed 20153028 -
Management of cervical carcinoma stage IV: comment.
CME Journal of Gynecologic Oncology, 15 (1), 69-71
PublikaID 105 -
The treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 72-90
PublikaID 106 -
Surgery in treatment of recurrent cervical cancer
CME Journal of Gynecologic Oncology, 15 (1), 33-39
PublikaID 104 -
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
Int J Gynecol Cancer, 20 (3), 476-8
DOI 10.1111/IGC.0b013e3181d3caa8, PubMed 20375816 -
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer
N Engl J Med, 363 (10), 943-53
DOI 10.1056/NEJMoa0908806, PubMed 20818904 -
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial
Eur J Cancer, 47 (1), 57-64
DOI 10.1016/j.ejca.2010.08.008, PubMed 20850296 -
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes
BMC Cancer, 10, 233
DOI 10.1186/1471-2407-10-233, PubMed 20500813 -
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
Diagn Cytopathol, 39 (8), 562-6
DOI 10.1002/dc.21424, PubMed 20730893
Publications 2009
-
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients
Histopathology, 54 (3), 355-64
DOI 10.1111/j.1365-2559.2009.03231.x, PubMed 19236512 -
Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol, 20 Suppl 4, 29-31
DOI 10.1093/annonc/mdp120, PubMed 19454455 -
Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
Hum Pathol, 40 (5), 705-13
DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507 -
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
Am J Clin Pathol, 132 (5), 756-62
DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818 -
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
Int J Gynecol Pathol, 28 (3), 211-21
DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938 -
Beta-catenin expression in uterine sarcomas and its relation to clinicopathological parameters
Eur J Cancer, 45 (13), 2412-7
DOI 10.1016/j.ejca.2009.06.017, PubMed 19622417 -
A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice
J Clin Pathol, 62 (3), 212-8
DOI 10.1136/jcp.2008.057240, PubMed 19251952 -
Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer
PLoS Genet, 5 (11), e1000719
DOI 10.1371/journal.pgen.1000719, PubMed 19911042 -
Morbidity associated with "self-rated health" in epithelial ovarian cancer survivors
BMC Cancer, 9, 2
DOI 10.1186/1471-2407-9-2, PubMed 19121203 -
Prevalence and determinants of metabolic syndrome and elevated Framingham risk score in epithelial ovarian cancer survivors: a controlled observational study
Int J Gynecol Cancer, 19 (4), 634-40
DOI 10.1111/IGC.0b013e3181a13058, PubMed 19509562 -
A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer
Gynecol Oncol, 113 (1), 128-33
DOI 10.1016/j.ygyno.2008.12.024, PubMed 19178933 -
Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer
Int J Gynecol Cancer, 19 (6), 1029-36
DOI 10.1111/IGC.0b013e3181a83cd5, PubMed 19820364 -
Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis
PLoS One, 4 (5), e5583
DOI 10.1371/journal.pone.0005583, PubMed 19440550 -
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
Virchows Arch, 454 (6), 677-83
DOI 10.1007/s00428-009-0778-y, PubMed 19421773 -
Robot assisted laparoscopic radical hysterectomy and pelvic lymphadenectomy with short and long term morbidity
Gynecol Oncol, 115 (1), 164-165
DOI 10.1016/j.ygyno.2009.05.028, PubMed 19539356 -
Robot-assisted laparoscopic surgery in gynaecological oncology; initial experience at Oslo Radium Hospital and 16 months follow-up
Int J Med Robot, 5 (4), 410-4
DOI 10.1002/rcs.272, PubMed 19569081 -
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
PubMed 19899396 -
[From wonder to alarm--the Tidsskriftet, the Nobel Prize and the HPV vaccine]
Tidsskr Nor Laegeforen, 129 (7), 651; author reply 651
DOI 10.4045/tidsskr.09.0067, PubMed 19337352 -
Ultrasound guidance for peripheral nerve blockade
Cochrane Database Syst Rev (4), CD006459
DOI 10.1002/14651858.CD006459.pub2, PubMed 19821368 -
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
Hum Pathol, 40 (10), 1453-60
DOI 10.1016/j.humpath.2009.02.013, PubMed 19454358
Publications 2008
-
Endometrial carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up
Ann Oncol, 19 Suppl 2, ii19-20
DOI 10.1093/annonc/mdn113, PubMed 18456753 -
Large mammographic opacity due to hamartoma
JBR-BTR, 91 (4), 177
PubMed 18817100 -
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
Cancer, 112 (1), 84-93
DOI 10.1002/cncr.23140, PubMed 17985388 -
Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: a controlled, population-based study (HUNT-2)
Gynecol Oncol, 109 (3), 377-83
DOI 10.1016/j.ygyno.2008.02.025, PubMed 18407340 -
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
J Med Genet, 46 (9), 593-7
DOI 10.1136/jmg.2008.058248, PubMed 18413372 -
Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis
Int J Med Sci, 5 (3), 121-6
DOI 10.7150/ijms.5.121, PubMed 18566674 -
Human papillomavirus DNA and e6/e7 mRNA status in relation to survival of patients treated for cervical squamous cell carcinoma
Open Virol J, 2, 74-81
DOI 10.2174/1874357900802010074, PubMed 19440467 -
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
Hum Pathol, 39 (5), 747-57
DOI 10.1016/j.humpath.2007.10.002, PubMed 18439941 -
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
Diagn Cytopathol, 36 (9), 637-44
DOI 10.1002/dc.20879, PubMed 18677760 -
SLNB and the importance of micrometastases in vulvar squamous cell carcinoma
Surg Oncol, 17 (3), 219-25
DOI 10.1016/j.suronc.2008.05.001, PubMed 18556194 -
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer
J Clin Oncol, 26 (16), 2674-82
DOI 10.1200/JCO.2007.14.9807, PubMed 18509179 -
GeneCount: genome-wide calculation of absolute tumor DNA copy numbers from array comparative genomic hybridization data
Genome Biol, 9 (5), R86
DOI 10.1186/gb-2008-9-5-r86, PubMed 18500990 -
Consistent numerical chromosome aberrations in thecofibromas of the ovary
Virchows Arch, 452 (3), 269-76
DOI 10.1007/s00428-007-0561-x, PubMed 18188592 -
Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study
Eur J Cancer, 45 (1), 82-9
DOI 10.1016/j.ejca.2008.09.028, PubMed 19008092 -
The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer
Ann Oncol, 20 (2), 286-93
DOI 10.1093/annonc/mdn591, PubMed 18725390 -
Is the watch and wait approach adequate after comprehensive surgical staging in invasive stage I epithelial ovarian cancer? The Norwegian Radium Hospital experience
Eur J Gynaecol Oncol, 29 (6), 583-9
PubMed 19115683 -
Clinical recommendations of European Society for Medical Oncology for diagnosis, treatment and follow-up of selected cancer in women
Oncol. Clin. Pract., 4 (4), 145-154 -
Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?
Int J Radiat Oncol Biol Phys, 71 (5), 1335-42
DOI 10.1016/j.ijrobp.2007.12.030, PubMed 18355976 -
Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy
Int J Radiat Oncol Biol Phys, 73 (4), 1141-7
DOI 10.1016/j.ijrobp.2008.05.064, PubMed 18760883 -
The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas
BMC Cancer, 8, 308
DOI 10.1186/1471-2407-8-308, PubMed 18950492
Publications 2007
-
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
Hum Pathol, 38 (7), 1030-1036
DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728 -
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Cancer, 110 (6), 1264-71
DOI 10.1002/cncr.22918, PubMed 17647260 -
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
Mol Cancer, 6, 12
DOI 10.1186/1476-4598-6-12, PubMed 17274819 -
Expression of ZNF652, a novel zinc finger protein, in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 61 (1), 59-63
DOI 10.1136/jcp.2006.045864, PubMed 17468294 -
The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma
Int J Gynecol Pathol, 26 (4), 418-25
DOI 10.1097/pgp.0b013e31804216a0, PubMed 17885492 -
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
Cancer, 109 (2), 228-38
DOI 10.1002/cncr.22426, PubMed 17167759 -
A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach
Gynecol Oncol, 108 (2), 348-54
DOI 10.1016/j.ygyno.2007.10.009, PubMed 17996925 -
Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones?
J Clin Oncol, 25 (15), 2049-56
DOI 10.1200/JCO.2006.09.1769, PubMed 17513809 -
Metabolic mapping by use of high-resolution magic angle spinning 1H MR spectroscopy for assessment of apoptosis in cervical carcinomas
BMC Cancer, 7, 11
DOI 10.1186/1471-2407-7-11, PubMed 17233882 -
Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer
Cancer, 109 (4), 645-9
DOI 10.1002/cncr.22467, PubMed 17238177 -
Improved survival for stage IIIC ovarian cancer patients treated at the Norwegian Radium Hospital between 1984 and 2001
Eur J Gynaecol Oncol, 28 (4), 256-62
PubMed 17713088 -
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213 -
Robotic radical hysterectomy in early-stage cervical carcinoma patients, comparing results with total laparoscopic radical hysterectomy cases. The future is now?
Int J Med Robot, 3 (3), 224-8
DOI 10.1002/rcs.152, PubMed 17924449 -
Clinical trials in gynecological cancer
Int J Gynecol Cancer, 17 (3), 547-56
DOI 10.1111/j.1525-1438.2007.00667.x, PubMed 17504371 -
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
J Clin Oncol, 25 (20), 2909-20
DOI 10.1200/JCO.2007.11.1013, PubMed 17617522 -
ESGO statement on cervical cancer vaccination
Int J Gynecol Cancer, 17 (6), 1183-5
DOI 10.1111/j.1525-1438.2007.01129.x, PubMed 17997794 -
Chronic fatigue and its correlates in long-term survivors of cervical cancer treated with radiotherapy
BJOG, 114 (9), 1150-8
DOI 10.1111/j.1471-0528.2007.01445.x, PubMed 17655733 -
The sexual activity questionnaire: pychometric properties and normative data in a norwegian population sample
J Womens Health (Larchmt), 16 (1), 139-48
DOI 10.1089/jwh.2006.0052, PubMed 17324105 -
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients
Ann Oncol, 18 (5), 964-6
DOI 10.1093/annonc/mdm134, PubMed 17488735 -
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers
Epigenetics, 2 (4), 237-43
DOI 10.4161/epi.2.4.5406, PubMed 18281782 -
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets
Mol Cancer, 6, 45
DOI 10.1186/1476-4598-6-45, PubMed 17623056 -
Expression of seprase in effusions from patients with epithelial ovarian carcinoma
Chin Med J (Engl), 120 (8), 663-8
PubMed 17517181
Publications 2006
-
An international perspective on surgical health care and education
J Am Coll Surg, 204 (1), 148-57
DOI 10.1016/j.jamcollsurg.2006.09.021, PubMed 17189123 -
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
Pathology, 38 (2), 145-51
DOI 10.1080/00313020600561526, PubMed 16680901 -
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
BMC Clin Pharmacol, 6, 2
DOI 10.1186/1472-6904-6-2, PubMed 16412237 -
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers
PLoS Med, 3 (3), e47
DOI 10.1371/journal.pmed.0030047, PubMed 16417408 -
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
Clin Cancer Res, 12 (3 Pt 1), 791-9
DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090 -
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
Gynecol Oncol, 104 (2), 311-9
DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350 -
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
Gynecol Oncol, 103 (3), 814-9
DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205 -
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
Am J Clin Pathol, 125 (3), 451-8
DOI 10.1309/15B66DQMFYYM78CJ, PubMed 16613351 -
Expression of E-cadherin transcriptional regulators in ovarian carcinoma
Virchows Arch, 449 (5), 520-8
DOI 10.1007/s00428-006-0274-6, PubMed 17024425 -
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
Gynecol Oncol, 103 (3), 831-40
DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315 -
Expression of EphA2 and EphrinA-1 in vulvar carcinomas and its relation to prognosis
J Clin Pathol, 60 (10), 1086-91
DOI 10.1136/jcp.2006.041194, PubMed 17158642 -
Cell cycle regulation in primary vulvar carcinomas and related lymph node metastases
Histopathology, 49 (3), 311-2
DOI 10.1111/j.1365-2559.2006.02457.x, PubMed 16918980 -
p14ARF, a prognostic predictor in HPV-negative vulvar carcinoma
Am J Clin Pathol, 126 (2), 266-76
DOI 10.1309/e9e8y9wg5qe3lk29, PubMed 16891203 -
Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique
Cancer Immunol Immunother, 55 (10), 1280-4
DOI 10.1007/s00262-006-0121-2, PubMed 16429314 -
Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas
J Clin Microbiol, 44 (4), 1310-7
DOI 10.1128/JCM.44.4.1310-1317.2006, PubMed 16597856 -
Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
BMC Genomics, 7, 268
DOI 10.1186/1471-2164-7-268, PubMed 17054779 -
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique
Clin Exp Immunol, 144 (1), 53-8
DOI 10.1111/j.1365-2249.2006.03031.x, PubMed 16542365 -
Ovarian cancer stage IIIC. Consequences of treatment level on overall and progression-free survival
Eur J Gynaecol Oncol, 27 (3), 209-14
PubMed 16800244 -
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Gynecol Oncol, 102 (3), 447-52
DOI 10.1016/j.ygyno.2006.01.035, PubMed 16516277 -
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Int J Gynecol Cancer, 16 Suppl 1, 11-7
DOI 10.1111/j.1525-1438.2006.00319.x, PubMed 16515561 -
Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas
Mod Pathol, 19 (9), 1227-35
DOI 10.1038/modpathol.3800641, PubMed 16729014 -
A new approach to treatment of early-stage cervical carcinoma: entire laparoscopic abdominal radical hysterectomy with bilateral pelvic lymphadenectomy without vaginal cuff closure--case reports
Eur J Gynaecol Oncol, 27 (5), 513-8
PubMed 17139990 -
Primary surgery for ovarian cancer
Eur J Surg Oncol, 32 (8), 844-52
DOI 10.1016/j.ejso.2006.03.036, PubMed 16677797 -
Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (vol 24, pg 21, 2004)
Hum. Mutat., 27 (2), 209-210
DOI 10.1002/humu.20298 -
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma
Gynecol Oncol, 102 (1), 15-21
DOI 10.1016/j.ygyno.2005.11.034, PubMed 16499955
Publications 2005
-
High-resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas
Genes Chromosomes Cancer, 42 (3), 228-37
DOI 10.1002/gcc.20128, PubMed 15578687 -
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Cancer Res, 65 (1), 331-7
PubMed 15665311 -
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
Gynecol Oncol, 96 (1), 42-7
DOI 10.1016/j.ygyno.2004.09.049, PubMed 15589578 -
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am J Clin Pathol, 123 (3), 360-8
DOI 10.1309/PTBB-5BPC-KX8K-9V69, PubMed 15716231 -
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
Ann Oncol, 16 Suppl 8, viii7-viii12
DOI 10.1093/annonc/mdi961, PubMed 16239238 -
Prevalence and histologic diagnosis of adnexal cysts in postmenopausal women: an autopsy study
Am J Obstet Gynecol, 192 (1), 48-54
DOI 10.1016/j.ajog.2004.07.038, PubMed 15672002 -
Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence
Am J Obstet Gynecol, 193 (3 Pt 1), 650-7
DOI 10.1016/j.ajog.2005.01.056, PubMed 16150255 -
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
Cancer, 103 (8), 1631-43
DOI 10.1002/cncr.20946, PubMed 15742334 -
CT colonography with fecal tagging after incomplete colonoscopy
Eur Radiol, 15 (6), 1192-202
DOI 10.1007/s00330-005-2644-x, PubMed 15702335 -
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas
Gynecol Oncol, 99 (2), 278-86
DOI 10.1016/j.ygyno.2005.06.036, PubMed 16061279 -
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
Int J Gynecol Cancer, 15 (6), 1014-22
DOI 10.1111/j.1525-1438.2005.00185.x, PubMed 16343177 -
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients
Eur J Cancer, 41 (8), 1127-34
DOI 10.1016/j.ejca.2005.01.022, PubMed 15911235 -
Cyclins D1, D3, E, and A in vulvar carcinoma patients
Gynecol Oncol, 97 (3), 733-9
DOI 10.1016/j.ygyno.2005.03.025, PubMed 15894358 -
Occult lymph node metastases in early stage vulvar carcinoma patients
Gynecol Oncol, 99 (2), 383-7
DOI 10.1016/j.ygyno.2005.06.023, PubMed 16051338 -
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival
BMC Cancer, 5, 134
DOI 10.1186/1471-2407-5-134, PubMed 16229746 -
[Primary treatment of ovarian cancer]
Tidsskr Nor Laegeforen, 125 (3), 278-81
PubMed 15702146 -
Fibrolamellar hepatocellular carcinoma in a 65-year-old woman: CT features
JBR-BTR, 88 (5), 237-40
PubMed 16302333 -
Symptoms and referral of women with epithelial ovarian tumors
Int J Gynaecol Obstet, 88 (1), 31-7
DOI 10.1016/j.ijgo.2004.09.008, PubMed 15617702 -
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
Diagn Cytopathol, 33 (5), 332-7
DOI 10.1002/dc.20296, PubMed 16240397 -
[Molecular diagnostic techniques in gynaecologic cancer]
Tidsskr Nor Laegeforen, 125 (22), 3120-3
PubMed 16299569 -
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759 -
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
Proc Natl Acad Sci U S A, 102 (39), 14004-9
DOI 10.1073/pnas.0504195102, PubMed 16172393 -
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
Cancer, 103 (11), 2313-9
DOI 10.1002/cncr.21031, PubMed 15844177 -
3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration
Ann Oncol, 16 Suppl 8, viii36-viii38
DOI 10.1093/annonc/mdi965, PubMed 16239235 -
Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
Ann Oncol, 16 Suppl 8, viii13-viii19
DOI 10.1093/annonc/mdi962, PubMed 16239232 -
Markers of apoptosis in stage IB squamous cervical carcinoma
J Clin Pathol, 58 (6), 590-4
DOI 10.1136/jcp.2004.021220, PubMed 15917408 -
Risk grouping in stage IB squamous cell cervical carcinoma
Gynecol Oncol, 99 (1), 106-12
DOI 10.1016/j.ygyno.2005.05.026, PubMed 16137752 -
Re: "P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma"
Gynecol Oncol, 98 (2), 335-6
DOI 10.1016/j.ygyno.2004.09.011, PubMed 16039312 -
PIK3CA mutations in advanced ovarian carcinomas
Hum Mutat, 25 (3), 322
DOI 10.1002/humu.9316, PubMed 15712344 -
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas
Am J Clin Pathol, 124 (3), 392-401
DOI 10.1309/BL7E-MW66-LQX6-GFRP, PubMed 16191507 -
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317
Publications 2004
-
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Gynecol Oncol, 95 (3), 430-6
DOI 10.1016/j.ygyno.2004.08.035, PubMed 15581943 -
BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study
Br J Cancer, 91 (10), 1829-34
DOI 10.1038/sj.bjc.6602199, PubMed 15477862 -
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
Cancer, 100 (10), 2139-47
DOI 10.1002/cncr.20219, PubMed 15139056 -
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
Clin Exp Metastasis, 21 (3), 191-9
DOI 10.1023/b:clin.0000037703.37275.35, PubMed 15387369 -
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
Lung Cancer, 44 (2), 159-65
DOI 10.1016/j.lungcan.2003.11.014, PubMed 15084380 -
Nordic gynecologists' opinion on quality assessment registers
Acta Obstet Gynecol Scand, 83 (6), 563-9
DOI 10.1111/j.0001-6349.2004.00514.x, PubMed 15144339 -
Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis
Anal Chem, 76 (15), 4406-9
DOI 10.1021/ac049788k, PubMed 15283579 -
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
Gynecol Oncol, 93 (2), 517-23
DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972 -
Deep vein thrombosis after elective cesarean section
Thromb Res, 113 (5), 283-8
DOI 10.1016/j.thromres.2004.03.008, PubMed 15183039 -
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables
Cancer Genet Cytogenet, 155 (1), 25-32
DOI 10.1016/j.cancergencyto.2004.02.010, PubMed 15527899 -
p16INK4a and p21Waf1/Cip1 expression correlates with clinical outcome in vulvar carcinomas
Gynecol Oncol, 95 (1), 37-45
DOI 10.1016/j.ygyno.2004.07.026, PubMed 15385108 -
Endometrial cancer: the management of high-risk disease
Curr Oncol Rep, 6 (6), 471-5
DOI 10.1007/s11912-004-0078-2, PubMed 15485617 -
Pyoderma gangrenosum as a cause of spontaneous vulvovaginal ulceration
Acta Obstet Gynecol Scand, 83 (12), 1220-1
DOI 10.1111/j.0001-6349.2004.0133b.x, PubMed 15548161 -
Intratumor chromosomal heterogeneity in advanced carcinomas of the uterine cervix
Int J Cancer, 111 (3), 358-66
DOI 10.1002/ijc.20258, PubMed 15221962 -
Primary ovarian small cell carcinoma of the pulmonary type: a case report and review of the literature
Eur J Gynaecol Oncol, 25 (2), 239-41
PubMed 15032292 -
Genomic aberrations in carcinomas of the uterine corpus
Genes Chromosomes Cancer, 40 (3), 229-46
DOI 10.1002/gcc.20038, PubMed 15139002 -
Papillary serous carcinoma of the ovary: an ultrastructural and immunohistochemical study
Ultrastruct Pathol, 28 (3), 141-7
DOI 10.1080/01913120490475716, PubMed 15471427 -
E-cadherin and catenins in early squamous cervical carcinoma
Gynecol Oncol, 94 (2), 521-7
DOI 10.1016/j.ygyno.2004.05.046, PubMed 15297198 -
Cyclins and proliferation markers in early squamous cervical carcinoma
Gynecol Oncol, 92 (1), 40-6
DOI 10.1016/j.ygyno.2003.10.022, PubMed 14751136 -
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
Gynecol. Oncol., 92 (2), 730
DOI 10.1016/j.ygyno.2003.10.042 -
Papillary serous adenocarcinoma of the endometrium: CT-pathologic correlation
AJR Am J Roentgenol, 182 (6), 1534-6
DOI 10.2214/ajr.182.6.1821534, PubMed 15150003 -
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival
Br J Cancer, 90 (3), 678-85
DOI 10.1038/sj.bjc.6601537, PubMed 14760384 -
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma
Hum Mutat, 24 (1), 21-34
DOI 10.1002/humu.20055, PubMed 15221786 -
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma
Pathol Oncol Res, 10 (4), 212-8
DOI 10.1007/BF03033763, PubMed 15619642 -
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma
Gynecol Oncol, 94 (2), 312-9
DOI 10.1016/j.ygyno.2004.05.019, PubMed 15297167 -
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
Gynecol Oncol, 94 (1), 80-5
DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123
Publications 2003
-
The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma
Cancer, 98 (9), 1880-9
DOI 10.1002/cncr.11727, PubMed 14584070 -
The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
Int J Gynecol Cancer, 13 Suppl 2, 163-8
DOI 10.1111/j.1525-1438.2003.13354.x, PubMed 14656274 -
ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit - Reply
Lancet, 362 (9392), 1334
DOI 10.1016/S0140-6736(03)14604-1 -
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 621-31
DOI 10.1023/a:1027347932543, PubMed 14669793 -
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
Clin Exp Metastasis, 20 (2), 161-9
DOI 10.1023/a:1022696012668, PubMed 12705637 -
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients
Gynecol Oncol, 90 (2), 248-57
DOI 10.1016/s0090-8258(03)00321-4, PubMed 12893184 -
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393 -
A systematic overview of radiation therapy effects in cervical cancer (cervix uteri)
Acta Oncol, 42 (5-6), 546-56
DOI 10.1080/02841860310014660, PubMed 14596512 -
A systematic overview of radiation therapy effects in uterine cancer (corpus uteri)
Acta Oncol, 42 (5-6), 557-61
DOI 10.1080/02841860310014417, PubMed 14596513 -
A systematic overview of radiation therapy effects in ovarian cancer
Acta Oncol, 42 (5-6), 562-6
DOI 10.1080/02841860310014426, PubMed 14596514 -
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
Gynecol Oncol, 91 (1), 160-72
DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677 -
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 599-609
DOI 10.1023/a:1027340208536, PubMed 14669791 -
Adnexal masses in pregnancy
Onkologie, 26 (2), 167-72
DOI 10.1159/000069838, PubMed 12771526 -
Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female
Hum Pathol, 34 (9), 946-9
DOI 10.1016/s0046-8177(03)00345-9, PubMed 14562293 -
Discussion: Metastasis and angiogenesis in epithelial ovarian cancer
Gynecol. Oncol., 88 (1), S37-S42
DOI 10.1006/gyno.2002.6681 -
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
Ann Oncol, 14 (10), 1494-500
DOI 10.1093/annonc/mdg403, PubMed 14504048 -
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
Int J Gynecol Cancer, 13 Suppl 2, 172-7
DOI 10.1111/j.1525-1438.2003.13363.x, PubMed 14656276 -
X chromosome inactivation in cervical cancer patients
Cancer Genet Cytogenet, 146 (1), 73-6
DOI 10.1016/s0165-4608(03)00152-3, PubMed 14499700 -
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Lancet, 361 (9375), 2099-106
DOI 10.1016/s0140-6736(03)13718-x, PubMed 12826431 -
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
Int J Gynecol Cancer, 13 Suppl 2, 144-8
DOI 10.1111/j.1525-1438.2003.13357.x, PubMed 14656271 -
Gene expression patterns in ovarian carcinomas
Mol Biol Cell, 14 (11), 4376-86
DOI 10.1091/mbc.e03-05-0279, PubMed 12960427 -
WNT-inducible signaling pathway protein 3, WISP-3, is mutated in microsatellite unstable gastrointestinal carcinomas but not in endometrial carcinomas
Gastroenterology, 124 (1), 270-1
DOI 10.1053/gast.2003.50034, PubMed 12512062 -
[Paclitaxel should be included in standard therapy of ovarian carcinoma]
Tidsskr Nor Laegeforen, 123 (21), 3083-4
PubMed 14618184 -
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
Gynecol Oncol, 89 (1), 140-7
DOI 10.1016/s0090-8258(03)00010-6, PubMed 12694668 -
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis (vol 89, pg 140, 2003)
Gynecol. Oncol., 90 (1), 231
DOI 10.1016/S0090-8258(03)00233-6
Publications 2002
-
Hormonal treatment of endometrial carcinoma
Expert Rev Anticancer Ther, 2 (1), 106-12
DOI 10.1586/14737140.2.1.106, PubMed 12113059 -
Irofulven (MGI Pharma)
Curr Opin Investig Drugs, 3 (10), 1517-26
PubMed 12431030 -
Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis
Gynecol Oncol, 87 (1), 71-6
DOI 10.1006/gyno.2002.6801, PubMed 12468345 -
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study
Br J Cancer, 87 (1), 61-4
DOI 10.1038/sj.bjc.6600350, PubMed 12085257 -
Brains and faces in holoprosencephaly: pre- and postnatal description of 30 cases
Ultrasound Obstet Gynecol, 19 (1), 24-38
DOI 10.1046/j.0960-7692.2001.00154.x, PubMed 11851965 -
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am J Clin Pathol, 117 (2), 225-34
DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219 -
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
Clin Exp Metastasis, 19 (2), 135-44
DOI 10.1023/a:1014582911680, PubMed 11964077 -
Optimisation of colon cleansing prior to computed tomographic colonography
JBR-BTR, 85 (6), 289-96
PubMed 12553658 -
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
Eur J Gynaecol Oncol, 23 (5), 383-9
PubMed 12440808 -
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
Int J Surg Pathol, 10 (3), 175-80
DOI 10.1177/106689690201000302, PubMed 12232570 -
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
Cancer, 94 (3), 707-12
DOI 10.1002/cncr.10250, PubMed 11857303 -
Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancy
Med Pediatr Oncol, 38 (3), 187-91; discussion 192
DOI 10.1002/mpo.1308, PubMed 11836719 -
Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991
Eur J Gynaecol Oncol, 23 (2), 93-103
PubMed 12013120 -
[Mass screening against endometrial cancer?]
Tidsskr Nor Laegeforen, 122 (18), 1767
PubMed 12362684 -
[Laparoscopic surgery in endometrial carcinoma]
Tidsskr Nor Laegeforen, 122 (25), 2429
PubMed 12448107
Publications 2001
-
Histologic subtype has minor importance for overall survival in patients with adenocarcinoma of the uterine cervix: a population-based study of prognostic factors in 505 patients with nonsquamous cell carcinomas of the cervix
Cancer, 92 (9), 2471-83
DOI 10.1002/1097-0142(20011101)92:9<2471::aid-cncr1597>3.0.co;2-k, PubMed 11745305 -
Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer
J Clin Oncol, 19 (12), 2983-93
DOI 10.1200/JCO.2001.19.12.2983, PubMed 11408493 -
Prevalence of human papillomavirus in elderly women with cervical cancer
Gynecol Obstet Invest, 52 (4), 248-51
DOI 10.1159/000052984, PubMed 11729338 -
Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer
J Clin Oncol, 19 (19), 3967-75
DOI 10.1200/JCO.2001.19.19.3967, PubMed 11579118 -
Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas
Anal Cell Pathol, 23 (2), 45-9
DOI 10.1155/2001/521873, PubMed 11904459 -
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am J Clin Pathol, 115 (4), 517-24
DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899 -
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin Cancer Res, 7 (11), 3457-64
PubMed 11705863 -
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
Eur J Cancer, 37 (16), 2040-9
DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382 -
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079 -
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
Am J Surg Pathol, 25 (12), 1493-500
DOI 10.1097/00000478-200112000-00004, PubMed 11717538 -
Frequency of nightly wetting and the efficiency of alarm treatment of nocturnal enuresis
Scand J Urol Nephrol, 35 (5), 357-63
DOI 10.1080/003655901753224404, PubMed 11771861 -
Serial changes in tumor oxygenation during the early phase of radiation therapy in cervical cancer - Are we quantitating hypoxia change? Response
Int. J. Radiat. Oncol. Biol. Phys., 49 (1), 285-289
DOI 10.1016/S0360-3016(00)00795-1 -
Intra- and intertumor heterogeneity in blood perfusion of human cervical cancer before treatment and after radiotherapy
Int J Cancer, 96 (3), 182-90
DOI 10.1002/ijc.1019, PubMed 11410887 -
Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA-enhanced MR imaging
J Magn Reson Imaging, 14 (6), 750-6
DOI 10.1002/jmri.10016, PubMed 11747032 -
Surgical management of stage I and II vulvar cancer: the role of the sentinel node biopsy. Review of literature
Int J Gynecol Cancer, 11 (4), 255-62
DOI 10.1046/j.1525-1438.2001.011004255.x, PubMed 11520362 -
Fertility preservation in gynecologic cancer
Acta Obstet Gynecol Scand, 80 (9), 794-802
DOI 10.1034/j.1600-0412.2001.080009794.x, PubMed 11531628 -
[Examination, treatment and follow-up of ovarian cancer in Norway]
Tidsskr Nor Laegeforen, 121 (23), 2696-700
PubMed 11699376 -
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
Eur J Gynaecol Oncol, 22 (3), 223-7
PubMed 11501778 -
Clear-cell and papillary serous cancer: treatment options
Best Pract Res Clin Obstet Gynaecol, 15 (3), 433-46
DOI 10.1053/beog.2000.0187, PubMed 11476564 -
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
Lancet, 357 (9251), 176-82
DOI 10.1016/S0140-6736(00)03590-X, PubMed 11213094
Publications 2000
-
[Early stage ovarian carcinoma--diagnosis and treatment]
Tidsskr Nor Laegeforen, 120 (4), 476-8
PubMed 10833940 -
Histopathologic subtyping of cervical adenocarcinoma reveals increasing incidence rates of endometrioid tumors in all age groups: a population based study with review of all nonsquamous cervical carcinomas in Norway from 1966 to 1970, 1976 to 1980, and 1986 to 1990
Cancer, 89 (6), 1291-9
DOI 10.1002/1097-0142(20000915)89:6<1291::AID-CNCR14>3.3.CO;2-F, PubMed 11002225 -
Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer
J Clin Oncol, 18 (22), 3775-81
DOI 10.1200/JCO.2000.18.22.3775, PubMed 11078490 -
Carcinoma of the fallopian tube
Cancer, 89 (10), 2076-84
PubMed 11066048 -
P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
Anticancer Res, 20 (2B), 1061-7
PubMed 10810398 -
[Epithelial ovarian cancer (advanced stage): consensus conference (1998)]
Gynecol Obstet Fertil, 28 (7-8), 576-83
PubMed 10996969 -
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
Clin Exp Metastasis, 18 (2), 197-202
DOI 10.1023/a:1006711320107, PubMed 11235996 -
[Screening for ovarian cancer]
Tidsskr Nor Laegeforen, 120 (12), 1444-8
PubMed 10851943 -
Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment
Acta Oncol, 39 (2), 173-80
DOI 10.1080/028418600430734, PubMed 10859007 -
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J Pathol, 192 (4), 460-9
DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH726>3.0.CO;2-M, PubMed 11113863 -
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum Pathol, 31 (9), 1081-7
DOI 10.1053/hupa.2000.9776, PubMed 11014575 -
Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival
Int J Cancer, 88 (2), 217-22
DOI 10.1002/1097-0215(20001015)88:2<217::aid-ijc11>3.0.co;2-i, PubMed 11004671 -
DNA copy number changes in malignant ovarian germ cell tumors
Cancer Res, 60 (11), 3025-30
PubMed 10850452 -
Changes in tumor oxygen tension during radiotherapy of uterine cervical cancer: relationships to changes in vascular density, cell density, and frequency of mitosis and apoptosis
Int J Radiat Oncol Biol Phys, 46 (4), 935-46
DOI 10.1016/s0360-3016(99)00497-6, PubMed 10705016 -
Disease control of uterine cervical cancer: relationships to tumor oxygen tension, vascular density, cell density, and frequency of mitosis and apoptosis measured before treatment and during radiotherapy
Clin Cancer Res, 6 (3), 1104-12
PubMed 10741740 -
Controversies in surgical management of advanced ovarian cancer (stage III-IV)
Eur J Gynaecol Oncol, 21 (5), 449-60
PubMed 11198031 -
Percutaneous treatment of acute multiple limb ischemia
JBR-BTR, 83 (5), 238-42
PubMed 11201538 -
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
DOI 10.1006/gyno.1999.5699, PubMed 10684705 -
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
J Natl Cancer Inst, 92 (9), 699-708
DOI 10.1093/jnci/92.9.699, PubMed 10793106 -
Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis
Br J Cancer, 83 (3), 354-9
DOI 10.1054/bjoc.2000.1266, PubMed 10917551 -
Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization
Radiother Oncol, 54 (2), 101-7
DOI 10.1016/s0167-8140(99)00175-9, PubMed 10699471 -
Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women
Int J Cancer, 87 (2), 232-5
PubMed 10861480 -
[Ovarian cancer screening of high risk groups]
Tidsskr Nor Laegeforen, 120 (18), 2191
PubMed 11006746 -
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
Ann Oncol, 11 (3), 281-8
DOI 10.1023/a:1008399414923, PubMed 10811493 -
Tamoxifen in the treatment of recurrent ovarian carcinoma
Eur J Cancer, 36 Suppl 4, S59-61
DOI 10.1016/s0959-8049(00)00228-8, PubMed 11056321 -
[Controversies in surgical treatment of advanced ovarian cancer]
Tidsskr Nor Laegeforen, 120 (7), 824-30
PubMed 10806907 -
[DNA ploidy in epithelial ovarian cancer--an independent prognostic factor]
Tidsskr Nor Laegeforen, 120 (1), 43-9
PubMed 10815478 -
[Borderline tumors of the ovary]
Tidsskr Nor Laegeforen, 120 (23), 2764-70
PubMed 11107921 -
Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide
Eur J Gynaecol Oncol, 21 (3), 255-9
PubMed 10949388 -
Surgery for borderline tumor of the ovary
Semin Surg Oncol, 19 (1), 69-75
DOI 10.1002/1098-2388(200007/08)19:1<69::aid-ssu11>3.0.co;2-e, PubMed 10883027 -
Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup
J Natl Cancer Inst, 92 (18), 1534-5
DOI 10.1093/jnci/92.18.1534, PubMed 10995813 -
High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers
Cancer Res, 60 (4), 916-21
PubMed 10706105 -
[Hyperbaric oxygen treatment for radiation reactions]
Tidsskr Nor Laegeforen, 120 (9), 1020-2
PubMed 10833959